Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

NCT06034275 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
B-cell Acute Lymphoblastic Leukemia
High-risk Myelodysplastic Syndrome

Interventions

DRUG: VIP943 (QW)
DRUG: VIP943 (BIW)

Sponsor

Vincerx Pharma, Inc.